<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://urologyschool.com/wikiuro/index.php?action=history&amp;feed=atom&amp;title=CUA%3A_Small_Renal_Masses_%282015%29</id>
	<title>CUA: Small Renal Masses (2015) - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://urologyschool.com/wikiuro/index.php?action=history&amp;feed=atom&amp;title=CUA%3A_Small_Renal_Masses_%282015%29"/>
	<link rel="alternate" type="text/html" href="https://urologyschool.com/wikiuro/index.php?title=CUA:_Small_Renal_Masses_(2015)&amp;action=history"/>
	<updated>2026-05-20T19:07:28Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.42.1</generator>
	<entry>
		<id>https://urologyschool.com/wikiuro/index.php?title=CUA:_Small_Renal_Masses_(2015)&amp;diff=1403&amp;oldid=prev</id>
		<title>Urology4all: Created page with &quot;  &#039;&#039;&#039;See Original Guideline&#039;&#039;&#039;  ===== Background =====  * &#039;&#039;&#039;Definition of small renal mass (SRM):&#039;&#039;&#039;  #* &#039;&#039;&#039;Enhancing tumours&#039;&#039;&#039; #* &#039;&#039;&#039;&lt;4 cm in diameter&#039;&#039;&#039; #* &#039;&#039;&#039;with image characteristics consistent with stage T1aN0M0 renal cell carcinoma&#039;&#039;&#039;  * Most SRMs are RCCs, ≈20-25% of SRMs are benign * Even if SRMs are malignant, most of them grow slowly * &#039;&#039;&#039;Small RCCs may be associated with metastatic disease at diagnosis in up to 8% of cases, so initial staging of all SRM p...&quot;</title>
		<link rel="alternate" type="text/html" href="https://urologyschool.com/wikiuro/index.php?title=CUA:_Small_Renal_Masses_(2015)&amp;diff=1403&amp;oldid=prev"/>
		<updated>2022-11-11T19:46:19Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;  &amp;#039;&amp;#039;&amp;#039;See Original Guideline&amp;#039;&amp;#039;&amp;#039;  ===== Background =====  * &amp;#039;&amp;#039;&amp;#039;Definition of small renal mass (SRM):&amp;#039;&amp;#039;&amp;#039;  #* &amp;#039;&amp;#039;&amp;#039;Enhancing tumours&amp;#039;&amp;#039;&amp;#039; #* &amp;#039;&amp;#039;&amp;#039;&amp;lt;4 cm in diameter&amp;#039;&amp;#039;&amp;#039; #* &amp;#039;&amp;#039;&amp;#039;with image characteristics consistent with stage T1aN0M0 renal cell carcinoma&amp;#039;&amp;#039;&amp;#039;  * Most SRMs are RCCs, ≈20-25% of SRMs are benign * Even if SRMs are malignant, most of them grow slowly * &amp;#039;&amp;#039;&amp;#039;Small RCCs may be associated with metastatic disease at diagnosis in up to 8% of cases, so initial staging of all SRM p...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;See Original Guideline&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
&lt;br /&gt;
===== Background =====&lt;br /&gt;
&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Definition of small renal mass (SRM):&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
&lt;br /&gt;
#* &amp;#039;&amp;#039;&amp;#039;Enhancing tumours&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
#* &amp;#039;&amp;#039;&amp;#039;&amp;lt;4 cm in diameter&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
#* &amp;#039;&amp;#039;&amp;#039;with image characteristics consistent with stage T1aN0M0 renal cell carcinoma&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
&lt;br /&gt;
* Most SRMs are RCCs, ≈20-25% of SRMs are benign&lt;br /&gt;
* Even if SRMs are malignant, most of them grow slowly&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Small RCCs may be associated with metastatic disease at diagnosis in up to 8% of cases, so initial staging of all SRM patients is essential&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
&lt;br /&gt;
#* &amp;#039;&amp;#039;&amp;#039;Recall 2014 CUA Surgical Management of Renal Cell Carcinoma Consensus Statementrecommended investigations&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
#** &amp;#039;&amp;#039;&amp;#039;History and physical&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
#** &amp;#039;&amp;#039;&amp;#039;Labs: CBC, Cr, LFTs, calcium&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
#** &amp;#039;&amp;#039;&amp;#039;Imaging: cross-sectional of primary tumour, CXR/CT&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
&lt;br /&gt;
* Based on current data, initial active surveillance (AS) with delayed treatment for local progression appears to be a relatively safe initial management strategy&lt;br /&gt;
&lt;br /&gt;
===== &amp;#039;&amp;#039;&amp;#039;Role of needle core biopsy of SRMs&amp;#039;&amp;#039;&amp;#039; =====&lt;br /&gt;
&lt;br /&gt;
* Biopsy appears safe and at least 80% of first biopsies are diagnostic. Repeat biopsy may be considered.&lt;br /&gt;
* Multiple tumours may have different histology and tumour grade, so multiple and repeat biopsies may be required to accurately characterize tumour histology.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Biopsy for histologic characterization should be reserved for patients in whom the results might change management&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;However, biopsy is not yet a standard of care in Canada&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
&lt;br /&gt;
===== &amp;#039;&amp;#039;&amp;#039;Management of SRMs&amp;#039;&amp;#039;&amp;#039; =====&lt;br /&gt;
&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Options:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
** &amp;#039;&amp;#039;&amp;#039;Partial nephrectomy (recommended)&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
** &amp;#039;&amp;#039;&amp;#039;Laparoscopic radical nephrectomy&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
*** &amp;#039;&amp;#039;&amp;#039;Reserved for tumours not amenable to partial nephrectomy&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
** &amp;#039;&amp;#039;&amp;#039;Thermal ablation (RFA or cryotherapy)&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
*** &amp;#039;&amp;#039;&amp;#039;A biopsy should be obtained before or at the time of ablation&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
*** Morbidity is low; can be performed on an outpatient basis without general anesthesia in a cost-effective manner&lt;br /&gt;
*** Attractive approach in elderly and comorbid patients&lt;br /&gt;
*** &amp;#039;&amp;#039;&amp;#039;Long-term follow-up with imaging is required&amp;#039;&amp;#039;&amp;#039; and local recurrence occurs in up to 14% of patients.&lt;br /&gt;
*** Success rates decrease in tumours &amp;gt;3 cm in diameter&lt;br /&gt;
** &amp;#039;&amp;#039;&amp;#039;Active surveillance&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
*** &amp;#039;&amp;#039;&amp;#039;Low rates of progression, including a low rate of metastasis of 1-2%&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
**** &amp;#039;&amp;#039;&amp;#039;Likely underestimate as studies have limited follow-up and most SRMs&amp;#039;&amp;#039;&amp;#039; are not biopsy proven to be cancer&lt;br /&gt;
*** Long-term follow-up is required to establish the safety of this approach in the young and fit patient.&lt;br /&gt;
*** Prognostic factors for progression are poorly understood, but primary tumour growth rate is the most widely used trigger for delayed treatment&lt;br /&gt;
*** &amp;#039;&amp;#039;&amp;#039;Active surveillance with regular radiographic follow-up should be a primary consideration for SRMs in elderly and/ or infirm patients with multiple comorbidities that would make them high risk for intervention, and in those with limited life expectancy&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
*** &amp;#039;&amp;#039;&amp;#039;Suggested follow-up:&amp;#039;&amp;#039;&amp;#039; computed tomography (CT) or magnetic resonance imaging every 3 months in the first year, every 6 months in the next 2 years and every year thereafter. US may be reasonable to substitute for CT/MRI&lt;/div&gt;</summary>
		<author><name>Urology4all</name></author>
	</entry>
</feed>